Halofuginone inhibits serum-stimulated pericardial tissue retraction in vitro

Tissue Engineering

Volumn 10, Issue 7-8, 2004, Pages 1076-1083

  Marchion, Douglas C ^a   Weber, Patricia A ^b   Lomnitski, Liat ^c   Duran, Carlos M G ^b,d   Cheung, David T ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

^d International Heart Institute Montana Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; COLLAGEN; CYCLINE; CYTARABINE; CYTOCHALASIN B; CYTOCHALASIN D; HALOFUGINONE; MONOCLONAL ANTIBODY; PROCOLLAGEN; PROCOLLAGEN TYPE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECT; FIBROSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; PERICARDIAL TISSUE RETRACTION; PERICARDIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; SHEEP; TISSUE CONTRACTION; TISSUE EXPANSION; WOUND HEALING;

ANIMALS; CELL PROLIFERATION; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ORGAN SIZE; PERICARDIUM; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINES; QUINAZOLINONES; SERUM; SHEEP; TISSUE CULTURE TECHNIQUES; TISSUE ENGINEERING;

EID: 4544315023     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2004.10.1076     Document Type: Article

References (28)

1. David, T.E., Feindel, C.M., and Ropchan, G.V. Reconstruction of the left ventricle with autologous pericardium. J. Thorac. Cardiovasc. Surg. 94, 710, 1987.
2. Schlichter, A.J., Kreitzer, C., Mayorquim, R.C., Simon, J.L., Vazquez, H., Roman, M.I., and Kreutzer, G.O. Long-term follow-up of autologous pericardial valved conduits. Ann. Thorac. Surg. 62, 155, 1996.
3. Bortolotti, U., Gallo, J.I., Gabbay, S., Factor, S.M., Sisto, D., and Frater, R.W. Replacement of mitral valve chordae with autologous pericardium in dogs. Thorac. Cardiovasc. Surg. 32, 15, 1984.
4. Hjelms, E., Pohlner, P., Barratt-Boyes, B.G., and Gavin, J.B. Study of autologous pericardial patch-grafts in the right ventricular outflow tracts in growing and adult dogs. J. Thorac. Cardiovasc. Surg. 81, 120, 1981.
5. Cheung, D.T., Choo, S.J., Grobe, A.C., Marchion, D.C., Luo, H.H., Pang, D.C., Favara, B.E., Oury, J.H., and Duran, C.M. Behavior of vital and killed autologous pericardium in the descending aorta of sheep. J. Thorac. Cardiovasc. Surg. 118, 998, 1999.
6. Marchion, D.C., Pfau, J.C., Weber, P.A., Grobe, A.C., Duran, C.M.G., and Cheung, D.T. An in vitro model of pericardial tissue healing. Biomaterials 24, 89, 2003.
7. Reed, L.J., and Muench, L.H. A simple emthod of estimating fifty percent endpoints. Am. J. Hygiene 27, 493, 1938.
8. Peterkofsky, B. The effect of ascorbic acid on collagen polypeptide synthesis and proline hydroxylation during the growth of cultured fibroblasts. Arch. Biochem. Biophys. 152, 318, 1972.
9. Russell, J.E., and Manske, P.R. Ascorbic acid requirements for optimal flexor tendon repair in vitro. J. Orthop. Res. 9, 714, 1991.
10. Marchion, D.C., Pfau, J.C., Weber, P.A., Grobe, A.C., Duran, C.M., and Cheung, D.T. An in vitro model of pericardial tissue healing. Biomaterials 24, 89, 2003.
11. Frater, R.W., and Bodnar, E. Towards understanding the pericardium as valve substitute [editorial]. J. Heart Valve Dis. 1, 213, 1992.
12. Duran, C.M.G., and Gometza, B. New uses of pericardium for valve surgery. In: D'Alessandro, L.C., ed. Heart Surgery. Rome: Casa Editrice Scientifica Internazionale, 1993, p. 69.
13. Nagler, A., Miao, H.Q., Aingorn, H., Pines, M., Genina, O., and Vlodavsky, I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler. Thromb. Vasc. Biol. 17, 194, 1997.
14. Granot, I., Bartov, I., Plavnik, I., Wax, E., Hurwitz, S., and Pines, M. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult. Sci. 70, 1559, 1991.
15. McGaha, T.L., Phelps, R.G., Spiera, H., and Bona, C. Halofuginone, an inhibitor of type-1 collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 118, 461, 2002.
16. McGaha, T.L., Kodera, T., Spiera, H., Stan, A.C., Pines, M., and Bona, C.A. Halofuginone inhibition of COLIA2 promotor activity via a c-Jun-dependent mechanism. Arthritis Rheum. 46, 2748, 2002.
17. Liu, K., Sekine, S., Goto, Y., Iijima, K., Yamagishi, I., Kondon, K., Matsukawa, M., and Abe, T. Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro. Heart Vessels 13, 18, 1998.
18. Granot, I., Halevy, O., Hurwitz, S., and Pines, M. Halofuginone: An inhibitor of collagen type I synthesis. Biochim. Biophys. Acta 1156, 107, 1993.
19. Nagler, A., Firman, N., Feferman, R., Cotev, S., Pines, M., and Shoshan, S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am. J. Respir. Crit. Care Med. 154, 1082, 1996.
20. Choi, E.T., Callow, A.D., Sehgal, N.L., Brown, D.M., and Ryan, U.S. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia. Arch. Surg. 130, 257, 1995.
21. Pines, M., Knopov, V., Genina, O., Lavelin, I., and Nagler, A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol. 27, 391, 1997.
22. Bruck, R., Genina, O., Aeed, H., Alexiev, R., Nagler, A., Avni, Y., and Pines, M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33, 379, 2001.
23. Nagler, A., Rivkind, A.I., Raphael, J., Levi-Schaffer, F., Genina, O., Lavelin, I., and Pines, M. Halofuginone-an inhibitor of collagen type I synthesis-prevents postoperative formation of abdominal adhesions. Ann. Surg. 227, 575, 1998.
24. Nagler, A., Genina, O., Lavelin, I., Ohana, M., and Pines, M. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Am. J. Obstet. Gynecol. 180, 558, 1999.
25. Abramovitch, R., Dafni, H., Neeman, M., Nagler, A., and Pines, M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1, 321, 1999.
26. Elkin, M., Reich, R., Nagler, A., Aingorn, E., Pines, M., de-Groot, N., Hochberg, A., and Vlodavsky, I. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin. Cancer Res. 5, 1982, 1999.
27. Nagler, A., and Pines, M. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: A novel inhibitor of collagen type I synthesis. Transplantation 68, 1806, 1999.
28. Nagler, A., Katz, A., Aingorn, H., Miao, H.Q., Condiotti, R., Genina, O., Pines, M., and Vlodavsky, I. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int. 52, 1561, 1997.